Abstract: The present invention relates to a fusion protein dimer comprising glucagon-like peptide-1 (GLP-1) and an interleukin-1 receptor antagonist (IL-1Ra), and a pharmaceutical composition for treating a metabolic disease using the same. It was confirmed that the fusion protein dimer significantly acts as a GLP-1 hormone and efficiently binds to an IL-1 receptor, and thus has an excellent inhibitory effect on the signaling of IL-1? caused by inflammasomes. Therefore, the fusion protein dimer according to the present invention has the combined efficacy of GLP-1 and an IL-1 receptor antagonist and can be effectively used for treatment and prevention of metabolic diseases such as diabetes, obesity, and hyperlipidemia, and thus has a high possibility of being industrially used.

Abstract: The present invention relates to a fusion protein dimer comprising an IgE Fc receptor alpha subunit extracellular domain (Fc?RI?-ECD) and a fragment of anti-IL-4R antibody; and a composition for treating allergic diseases, comprising the same. The fusion protein dimer according to the present invention exhibits an excellent IgE-binding ability and an excellent serum IgE level-reducing effect. In addition, the present invention elicits a hyperimmune response of IgE, and thus has an excellent effect of inhibiting the activity of cytokines inducing allergic diseases, such as IL-4 and IL-13, and thus may be applied as a medicine for the use of treating or preventing IgE-mediated allergic diseases.